Navigation Links
Bladder cancer recurrence and mortality could decline with better treatment compliance
Date:6/5/2013

Researchers at UCLA's Jonsson Comprehensive Cancer Center led by Dr. Karim Chamie have found that more intense surveillance and treatment of bladder cancer in the first two years after diagnosis could reduce the number of patients whose cancer returns after treatment and lower the disease's death rate. The study was published online ahead of press today in the journal Cancer.

Based on the team's previous research showing underutilization of care for patients with bladder cancer, this study is the first to examine the burden of the disease on the population. To date no one had examined the morbidity of recurrence of the disease in the U.S.

Chamie, assistant professor-in-residence in the UCLA department of urology, and his colleagues found that nearly three quarters of patients with high-grade, nonmuscle-invasive bladder cancer suffered a return of the disease within 10 years. In 33 percent of patients, the cancer progressed to a more advanced form requiring removal of the bladder, radiation therapy or systemic chemotherapy. And in an additional 41 percent, the cancer recurred without further spread of the disease.

"Even though 80 percent of bladder cancer patients don't die of their disease within five years, most patients will either die of other causes or bladder cancer, require aggressive treatment removal of the bladder, radiation and/or chemotherapy or have a recurrence of the disease," Chamie said. "This study highlights the need to comply with treatment guidelines to prevent recurrences by instilling anticancer agents inside the bladder and following patients more closely within the first two years of diagnosis."

The study was based on a nationwide sample of Medicare beneficiaries who had high-grade, nonmuscle-invasive bladder cancer. "We have Level I evidence that demonstrates that a single instillation of chemotherapy into the bladder can minimize recurrences, and that six instillations can minimize recurrence and progression," Chamie said. "Efforts should be increased to offer patients intravesical therapy with the goal of minimizing the burden of this disease."

The researchers also found that the burden of bladder cancer on the population is very high, and that the elderly, women and African-American patients had a higher likelihood of dying of bladder cancer than younger patients, men and white patients, respectively.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Chemo + Radiation Best for Bladder Cancer, Study Finds
2. Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
3. Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers
4. Study Ties Secondhand Smoke to Bladder Irritation in Kids
5. Vitamin D + TB vaccine: Allies in fight against bladder cancer?
6. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
7. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
8. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
9. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
10. Researchers Offer Explanation for Actos Bladder Cancer Risk
11. New Lawsuit alleges Actos caused Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... In 2011, ... work in the emerging field of biomechatronics, technology that marries human physiology with electromechanics. ... Media Lab. He is also the Founder of BionX , a leader in ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... One way ... say anything.” This is unfortunately true. But we toss the baby out with the ... single-page brief provides tips for identifying higher-quality studies and otherwise making better use of ...
(Date:4/28/2016)... Phoenix, AZ (PRWEB) , ... ... ... of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced ... The platform will provide efficient access to medical knowledge, educational resources, and ...
(Date:4/28/2016)... NC (PRWEB) , ... April 28, 2016 , ... ... announce it has partnered with Community Oncology Pharmacy Association (COPA) to develop a ... the practice of oncology by introducing an accreditation distinction. ACHC provides a wide ...
(Date:4/28/2016)... ... ... Baich had written poetry dating back to her childhood, but after several years without writing ... on a more spiritual tone. The desire to put the words on paper was very ... file it away. Friends would ask her how she wrote such wonderful poetry and her ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... Net Sales of $1.90 billion represent an increase of 67.8% ... an increase of 1.2% on an adjusted pro forma, constant ... were $0.52 reported, a decrease of 47.5% from the prior ... the prior year period , The Company increases constant ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
Breaking Medicine Technology: